Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This post-market clinical follow-up study intends to investigate the survival rate at 5 years of the e.motion® PS Pro System.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Total Knee prothesis e motion PS Pro | Device |
| Measure | Description | Time Frame |
|---|---|---|
| Survival rate at 5 years of the e motion PS Pro | The endpoint is the revision of at least one of the prosthesis components. If a patient withdraws from the study for any reason, counts as the end date for the survival of the implant of the last day on which the implants were well known even in place. | the survival rate will be evaluated 6-12 weeks; 1; 2; 3; 4 and 5 years after the knee arthroplasty |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients for which a Total Knee Prosthesis with e.motion® PS Pro was decided by the surgeon
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| François Boillot | Contact | 144123357 | +33 | fboillot@hpsj.fr |
| Boubker Zniber | Contact | 144123357 | bzniber@hpsj.fr |
| Name | Affiliation | Role |
|---|---|---|
| François Boillot | Groupe hospitalier Paris-St Joseph | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Groupe hospitalier Paris-St Joseph | Recruiting | Paris | 75014 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided